Moreover, while tumour regression was associated with decreased miR‐375 levels (RQ < 1, Figure 1C) in AIDS‐KS patients with lower CD4 cell counts, at both baseline and after treatment (Table 2), tumour persistence during PR or DP in non‐responders was associated with up‐regulated miR‐375, suggesting that this miRNA could be a circulating marker of tumour activity. This evidence concerns the gene CD4 and Kaposi's sarcoma.